A neurologist's guide to safe use of immunomodulatory therapies

Seminars in Neurology

Volumn 34, Issue 4, 2014, Pages 467-478

  Vodopivec, Ivana ^a,b   Miloslavsky, Eli M ^a,b   Kotton, Camille N ^a,b   Cho, Tracey A ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

glucocorticoid induced osteoporosis; immunosuppressive drugs; infection; infertility; intravenous immunoglobulin; malignancy; safety; vaccination

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; GLUCOCORTICOID; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MYCOPHENOLIC ACID; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; IMMUNOLOGIC FACTOR;

ADAPTIVE IMMUNITY; ARTICLE; BLOOD CELL COUNT; BONE NECROSIS; CHAGAS DISEASE; CLINICAL PRACTICE; CORTICOSTEROID INDUCED OSTEOPOROSIS; DEMYELINATING DISEASE; DRUG INDUCED DISEASE; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; GLUCOCORTICOID INDUCED OSTEONECROSIS; GLUCOCORTICOID INDUCED OSTEOPOROSIS; GONADAL DISEASE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HERPES ZOSTER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; LATENT TUBERCULOSIS; LEUKOCYTE COUNT; LIVER FUNCTION TEST; NEOPLASM; NEUROIMMUNOLOGY; NEUROLOGIST; NONHUMAN; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; SEROLOGY; STRONGYLOIDIASIS; THORAX RADIOGRAPHY; AUTOIMMUNE DISEASES OF THE NERVOUS SYSTEM; NEUROLOGY;

AUTOIMMUNE DISEASES OF THE NERVOUS SYSTEM; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; IMMUNOMODULATION; IMMUNOSUPPRESSIVE AGENTS; NEUROLOGY;

EID: 84928566149     PISSN: 02718235     EISSN: 10989021     Source Type: Journal    
DOI: 10.1055/s-0034-1390395     Document Type: Article

References (117)

1. Sarnes E., Crofford L., Watson M., Dennis G., Kan H., Bass D. Incidence and US costs of corticosteroid-associated adverse events: a systematic literature review. Clin Ther: 2011; 33 10 1413 1432
2. Flossmann O., Berden A., de Groot K., et al. European Vasculitis Study Group. Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis: 2011; 70 3 488 494
3. Wingerchuk D. M., Carter J. L. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies. Mayo Clin Proc: 2014; 89 2 225 240
4. Rice W. R., Singleton F. M., Linke M. J., Walzer P. D. Regulation of surfactant phosphatidylcholine secretion from alveolar type II cells during Pneumocystis carinii pneumonia in the rat. J Clin Invest: 1993; 92 6 2778 2782
5. Yale S. H., Limper A. H. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. Mayo Clin Proc: 1996; 71 1 5 13
6. Kadoya A., Okada J., Iikuni Y., Kondo H. Risk factors for Pneumocystis carinii pneumonia in patients with polymyositis/dermatomyositis or systemic lupus erythematosus. J Rheumatol: 1996; 23 7 1186 1188
7. Komano Y., Harigai M., Koike R., et al. Pneumocystis jiroveci pneumonia in patients with rheumatoid arthritis treated with infliximab: a retrospective review and case-control study of 21 patients. Arthritis Rheum: 2009; 61 3 305 312
8. Martin-Garrido I., Carmona E. M., Specks U., Limper A. H. Pneumocystis pneumonia in patients treated with rituximab. Chest: 2013; 144 1 258 265
9. Ward M. M., Donald F. Pneumocystis carinii pneumonia in patients with connective tissue diseases: the role of hospital experience in diagnosis and mortality. Arthritis Rheum: 1999; 42 4 780 789
10. Rodriguez M., Fishman J. A. Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients. Clin Microbiol Rev: 2004; 17 4 770 782 table of contents
11. Thomas C. F. Jr, Limper A. H. Pneumocystis pneumonia. N Engl J Med: 2004; 350 24 2487 2498
12. Mansharamani N. G., Balachandran D., Vernovsky I., Garland R., Koziel H. Peripheral blood CD4 + T-lymphocyte counts during Pneumocystis carinii pneumonia in immunocompromised patients without HIV infection. Chest: 2000; 118 3 712 720
13. Glück T., Geerdes-Fenge H. F., Straub R. H., et al. Pneumocystis carinii pneumonia as a complication of immunosuppressive therapy. Infection: 2000; 28 4 227 230
14. Limper A. H., Knox K. S., Sarosi G. A., et al. American Thoracic Society Fungal Working Group. An official American Thoracic Society statement: treatment of fungal infections in adult pulmonary and critical care patients. Am J Respir Crit Care Med: 2011; 183 1 96 128
15. Godeau B., Coutant-Perronne V., Le Thi Huong D., et al. Pneumocystis carinii pneumonia in the course of connective tissue disease: report of 34 cases. J Rheumatol: 1994; 21 2 246 251
16. Hwang J. P., Lok A. S. Management of patients with hepatitis B who require immunosuppressive therapy. Nat Rev Gastroenterol Hepatol: 2014; 11 4 209 219
17. Vassilopoulos D., Calabrese L. H. Management of rheumatic disease with comorbid HBV or HCV infection. Nat Rev Rheumatol: 2012; 8 6 348 357
18. Mitka M. FDA: Increased HBV reactivation risk with ofatumumab or rituximab. JAMA: 2013; 310 16 1664
19. Evens A. M., Jovanovic B. D., Su Y. C., et al. Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. Ann Oncol: 2011; 22 5 1170 1180
20. Pérez-Alvarez R., Díaz-Lagares C., García-Hernández F., et al. BIOGEAS Study Group. Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases. Medicine (Baltimore): 2011; 90 6 359 371
21. Juan J., Feld J. J. Hepatitis B virus and hepatitis C virus treatment and management in patients receiving immune-modifying agents. Curr Opin Rheumatol: 2014; 26 4 395 403
22. Flowers M. A., Heathcote J., Wanless I. R., et al. Fulminant hepatitis as a consequence of reactivation of hepatitis B virus infection after discontinuation of low-dose methotrexate therapy. Ann Intern Med: 1990; 112 5 381 382
23. Droz N., Gilardin L., Cacoub P., et al. Kinetic profiles and management of hepatitis B virus reactivation in patients with immune-mediated inflammatory diseases. Arthritis Care Res (Hoboken): 2013; 65 9 1504 1514
24. Le Boëdec M., Marhadour T., Devauchelle-Pensec V., et al. Baseline laboratory test abnormalities are common in early arthritis but rarely contraindicate methotrexate: study of three cohorts (ESPOIR, VErA, and Brittany). Semin Arthritis Rheum: 2013; 42 5 474 481
25. Saag K. G., Teng G. G., Patkar N. M., et al. American College of Rheumatology. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum: 2008; 59 6 762 784
26. Rubin L. G., Levin M. J., Ljungman P., et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis: 2014; 58 3 309 318
27. Smith B. D., Morgan R. L., Beckett G. A., et al. Centers for Disease Control and Prevention. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep: 2012; 61 (RR-4): 1 32
28. Brunasso A. M., Puntoni M., Gulia A., Massone C. Safety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection: a systematic review. Rheumatology (Oxford): 2011; 50 9 1700 1711
29. Gardam M. A., Keystone E. C., Menzies R., et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis: 2003; 3 3 148 155
30. Scott D. L., Kingsley G. H. Tumor necrosis factor inhibitors for rheumatoid arthritis. N Engl J Med: 2006; 355 7 704 712
31. Brassard P., Kezouh A., Suissa S. Antirheumatic drugs and the risk of tuberculosis. Clin Infect Dis: 2006; 43 6 717 722
32. Kim H. A., Yoo C. D., Baek H. J., et al. Mycobacterium tuberculosis infection in a corticosteroid-treated rheumatic disease patient population. Clin Exp Rheumatol: 1998; 16 1 9 13
33. Furst D. E., Keystone E. C., Fleischmann R., et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009. Ann Rheum Dis: 2010; 69 01 i2 i29
34. Singh J. A., Furst D. E., Bharat A., et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken): 2012; 64 5 625 639
35. Latent Tuberculosis Infection A Guide for Primary Health Care Providers. Available at: http://www.cdc.gov/tb/publications/LTBI/appendixA.htm. Accessed May 25, 2014
36. Smith R., Cattamanchi A., Steingart K. R., et al. Interferon-γ release assays for diagnosis of latent tuberculosis infection: evidence in immune-mediated inflammatory disorders. Curr Opin Rheumatol: 2011; 23 4 377 384
37. Winthrop K. L., Weinblatt M. E., Daley C. L. You can't always get what you want, but if you try sometimes (with two tests - TST and IGRA - for tuberculosis) you get what you need. Ann Rheum Dis: 2012; 71 11 1757 1760
38. Thomas S. L., Hall A. J. What does epidemiology tell us about risk factors for herpes zoster? Lancet Infect Dis: 2004; 4 1 26 33
39. Chen S. Y., Suaya J. A., Li Q., et al. Incidence of herpes zoster in patients with altered immune function. Infection: 2014; 42 2 325 334
40. Zhang J., Xie F., Delzell E., et al. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA: 2012; 308 1 43 49
41. Yawn B. P., Saddier P., Wollan P. C., St Sauver J. L., Kurland M. J., Sy L. S. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc: 2007; 82 11 1341 1349
42. Harpaz R., Ortega-Sanchez I. R., Seward J. F.; Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep: 2008; 57 05 1 30, quiz CE2-CE4
43. National Center for Immunization and Respiratory Diseases General recommendations on immunization - recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep: 2011; 60 2 1 64
44. Nagel M. A., Cohrs R. J., Mahalingam R., et al. The varicella zoster virus vasculopathies: clinical, CSF, imaging, and virologic features. Neurology: 2008; 70 11 853 860
45. Nagel M. A., Gilden D. Complications of varicella zoster virus reactivation. Curr Treat Options Neurol: 2013; 15 4 439 453
46. Iordache L., Launay O., Bouchaud O., et al. Associated authors. Autoimmune diseases in HIV-infected patients: 52 cases and literature review. Autoimmun Rev: 2014; 13 8 850 857
47. Lyons J., Venna N., Cho T. A. Atypical nervous system manifestations of HIV. Semin Neurol: 2011; 31 3 254 265
48. Morar N., Willis-Owen S. A., Maurer T., Bunker C. B. HIV-associated psoriasis: pathogenesis, clinical features, and management. Lancet Infect Dis: 2010; 10 7 470 478
49. Branson B. M., Handsfield H. H., Lampe M. A., et al. Centers for Disease Control and Prevention (CDC). Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep: 2006; 55 14 1 17, quiz CE1-CE4
50. Shah D., Flanigan T., Lally E. Routine screening for HIV in rheumatology practice. J Clin Rheumatol: 2011; 17 3 154 156
51. Nguyen B. Y., Reveille J. D. Rheumatic manifestations associated with HIV in the highly active antiretroviral therapy era. Curr Opin Rheumatol: 2009; 21 4 404 410
52. Yang J. J., Tsai M. S., Sun H. Y., et al. Autoimmune diseases-related arthritis in HIV-infected patients in the era of highly active antiretroviral therapy. J Microbiol Immunol Infect: 2013
53. Keyser F. D. Choice of biologic therapy for patients with rheumatoid arthritis: the infection perspective. Curr Rheumatol Rep: 2011; 7 1 77 87
54. Tan C. S., Koralnik I. J. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol: 2010; 9 4 425 437
55. Ferenczy M. W., Marshall L. J., Nelson C. D., et al. Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain. Clin Microbiol Rev: 2012; 25 3 471 506
56. Stolt A., Sasnauskas K., Koskela P., Lehtinen M., Dillner J. Seroepidemiology of the human polyomaviruses. J Gen Virol: 2003; 84 Pt 6 1499 1504
57. Antonsson A., Green A. C., Mallitt K. A., et al. Prevalence and stability of antibodies to the BK and JC polyomaviruses: a long-term longitudinal study of Australians. J Gen Virol: 2010; 91 Pt 7 1849 1853
58. Molloy E. S., Calabrese L. H. Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: evolving role of biologic therapies. Arthritis Rheum: 2012; 64 9 3043 3051
59. Molloy E. S. PML and rheumatology: the contribution of disease and drugs. Cleve Clin J Med: 2011; 78 02 S28 S32
60. Bloomgren G., Richman S., Hotermans C., et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med: 2012; 366 20 1870 1880
61. Neff R. T., Hurst F. P., Falta E. M., et al. Progressive multifocal leukoencephalopathy and use of mycophenolate mofetil after kidney transplantation. Transplantation: 2008; 86 10 1474 1478
62. Clifford D. B., Ances B., Costello C., et al. Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. Arch Neurol: 2011; 68 9 1156 1164
63. Greaves D., Coggle S., Pollard C., Aliyu S. H., Moore E. M. Strongyloides stercoralis infection. BMJ: 2013; 347 f4610
64. Buonfrate D., Requena-Mendez A., Angheben A., et al. Severe strongyloidiasis: a systematic review of case reports. BMC Infect Dis: 2013; 13 78
65. Bern C., Montgomery S. P. An estimate of the burden of Chagas disease in the United States. Clin Infect Dis: 2009; 49 5 e52 e54
66. van Assen S., Agmon-Levin N., Elkayam O., et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis: 2011; 70 3 414 422
67. van Assen S., Elkayam O., Agmon-Levin N., et al. Vaccination in adult patients with auto-immune inflammatory rheumatic diseases: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for vaccination in adult patients with auto-immune inflammatory rheumatic diseases. Autoimmun Rev: 2011; 10 6 341 352
68. Centers for Disease Control and Prevention (CDC) Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep: 2012; 61 40 816 819
69. Glück T., Müller-Ladner U. Vaccination in patients with chronic rheumatic or autoimmune diseases. Clin Infect Dis: 2008; 46 9 1459 1465
70. Oren S., Mandelboim M., Braun-Moscovici Y., et al. Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response. Ann Rheum Dis: 2008; 67 7 937 941
71. Bingham C. O. III, Looney R. J., Deodhar A., et al. Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. Arthritis Rheum: 2010; 62 1 64 74
72. Papadopoulou D., Sipsas N. V. Comparison of national clinical practice guidelines and recommendations on vaccination of adult patients with autoimmune rheumatic diseases. Rheumatol Int: 2014; 34 2 151 163
73. Kotton CN, Freedman DO. Immunocompromised Travelers (Chapter 8: Advising Travelers With Specific Needs).: 2013;. Available at: http://wwwnc.cdc.gov/travel/yellowbook/2014/chapter-8-advising-travelers-with-specific-needs/immunocompromised-travelers. Accessed May 24, 2014
74. Kotton C. N., Hibberd P. L.; AST Infectious Diseases Community of Practice. Travel medicine and transplant tourism in solid organ transplantation. Am J Transplant: 2013; 13 04 337 347
75. Weinstein R. S. Clinical practice. Glucocorticoid-induced bone disease. N Engl J Med: 2011; 365 1 62 70
76. Grossman J. M., Gordon R., Ranganath V. K., et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken): 2010; 62 11 1515 1526
77. Homik J., Suarez-Almazor M. E., Shea B., Cranney A., Wells G., Tugwell P. Calcium and vitamin D for corticosteroid-induced osteoporosis. Cochrane Database Syst Rev: 2000; 2 CD000952
78. Dore R. K. Long-term safety, efficacy, and patient acceptability of teriparatide in the management of glucocorticoid-induced osteoporosis. Patient Prefer Adherence: 2013; 7 435 446
79. Saag K. G., Shane E., Boonen S., et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med: 2007; 357 20 2028 2039
80. Rothman M. S., West S. G., McDermott M. T. Osteoporosis for the practicing neurologist. Neurol Clin Pract.: 2014; 4 3 183 184
81. Haugeberg G., Griffiths B., Sokoll K. B., Emery P. Bone loss in patients treated with pulses of methylprednisolone is not negligible: a short term prospective observational study. Ann Rheum Dis: 2004; 63 8 940 944
82. Assouline-Dayan Y., Chang C., Greenspan A., Shoenfeld Y., Gershwin M. E. Pathogenesis and natural history of osteonecrosis. Semin Arthritis Rheum: 2002; 32 2 94 124
83. Taylor L. J. Multifocal avascular necrosis after short-term high-dose steroid therapy. A report of three cases. J Bone Joint Surg Br: 1984; 66 3 431 433
84. Good A. E. Bilateral aseptic necrosis of femur following a 16-day course of corticotropin. JAMA: 1974; 228 4 497
85. Mankin H. J. Nontraumatic necrosis of bone (osteonecrosis). N Engl J Med: 1992; 326 22 1473 1479
86. Pecora P. G., Kaplan B. Corticosteroids and ulcers: is there an association? Ann Pharmacother: 1996; 30 7-8 870 872
87. Hernández-Díaz S., Rodríguez L. A. Steroids and risk of upper gastrointestinal complications. Am J Epidemiol: 2001; 153 11 1089 1093
88. Duru N., van der Goes M. C., Jacobs J. W., et al. EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis: 2013; 72 12 1905 1913
89. Mohan N., Edwards E. T., Cupps T. R., et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum: 2001; 44 12 2862 2869
90. Radis C. D., Kahl L. E., Baker G. L., et al. Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year followup study. Arthritis Rheum: 1995; 38 8 1120 1127
91. Bernatsky S., Clarke A. E., Suissa S. Hematologic malignant neoplasms after drug exposure in rheumatoid arthritis. Arch Intern Med: 2008; 168 4 378 381
92. Talar-Williams C., Hijazi Y. M., Walther M. M., et al. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med: 1996; 124 5 477 484
93. Faurschou M., Sorensen I. J., Mellemkjaer L., et al. Malignancies in Wegener's granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J Rheumatol: 2008; 35 1 100 105
94. Monach P. A., Arnold L. M., Merkel P. A. Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: a data-driven review. Arthritis Rheum: 2010; 62 1 9 21
95. Knight A., Askling J., Granath F., Sparen P., Ekbom A. Urinary bladder cancer in Wegener's granulomatosis: risks and relation to cyclophosphamide. Ann Rheum Dis: 2004; 63 10 1307 1311
96. Grossfeld G. D., Litwin M. S., Wolf J. S. Jr., et al. Evaluation of asymptomatic microscopic hematuria in adults: the American Urological Association best practice policy - Part II: patient evaluation, cytology, voided markers, imaging, cystoscopy, nephrology evaluation, and follow-up. Urology: 2001; 57 4 604 610
97. Hofland C. A., Mariani A. J. Is cytology required for a hematuria evaluation? J Urol: 2004; 171 1 324 326
98. Ramiro S., Gaujoux-Viala C., Nam J. L., et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis: 2014; 73 3 529 535
99. Penn I. Cancers complicating organ transplantation. N Engl J Med: 1990; 323 25 1767 1769
100. Fallah M., Liu X., Ji J., Försti A., Sundquist K., Hemminki K. Hodgkin lymphoma after autoimmune diseases by age at diagnosis and histological subtype. Ann Oncol: 2014; 25 7 1397 1404
101. Dias C., Isenberg D. A. Susceptibility of patients with rheumatic diseases to B-cell non-Hodgkin lymphoma. Nat Rev Rheumatol: 2011; 7 6 360 368
102. Raptopoulou A., Sidiropoulos P., Boumpas D. Ovarian failure and strategies for fertility preservation in patients with systemic lupus erythematosus. Lupus: 2004; 13 12 887 890
103. Blumenfeld Z., Mischari O., Schultz N., Boulman N., Balbir-Gurman A. Gonadotropin releasing hormone agonists may minimize cyclophosphamide associated gonadotoxicity in SLE and autoimmune diseases. Semin Arthritis Rheum: 2011; 41 3 346 352
104. Masala A., Faedda R., Alagna S., et al. Use of testosterone to prevent cyclophosphamide-induced azoospermia. Ann Intern Med: 1997; 126 4 292 295
105. Somers E. C., Marder W., Christman G. M., Ognenovski V., McCune W. J. Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus. Arthritis Rheum: 2005; 52 9 2761 2767
106. Henes M., Henes J. C., Neunhoeffer E., et al. Fertility preservation methods in young women with systemic lupus erythematosus prior to cytotoxic therapy: experiences from the FertiPROTEKT network. Lupus: 2012; 21 9 953 958
107. Elizur S. E., Chian R. C., Pineau C. A., et al. Fertility preservation treatment for young women with autoimmune diseases facing treatment with gonadotoxic agents. Rheumatology (Oxford): 2008; 47 10 1506 1509
108. Jones T. S., Yang W., Evans W. E., Relling M. V. Using HapMap tools in pharmacogenomic discovery: the thiopurine methyltransferase polymorphism. Clin Pharmacol Ther: 2007; 81 5 729 734
109. Wolach O., Bairey O., Lahav M. Late-onset neutropenia after rituximab treatment: case series and comprehensive review of the literature. Medicine (Baltimore): 2010; 89 5 308 318
110. Katsifis G. E., Tzioufas A. G., Vlachoyiannopoulos P. G., Voulgarelis M., Moutsopoulos H. M., Ioannidis J. P. Risk of myelotoxicity with intravenous cyclophosphamide in patients with systemic lupus erythematosus. Rheumatology (Oxford): 2002; 41 7 780 786
111. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines Guidelines for the management of rheumatoid arthritis: 2002 Update. Arthritis Rheum: 2002; 46 2 328 346
112. Anelli M. G., Scioscia C., Grattagliano I., Lapadula G. Old and new antirheumatic drugs and the risk of hepatotoxicity. Ther Drug Monit: 2012; 34 6 622 628
113. Alarcón G. S., Kremer J. M., Macaluso M., et al. Methotrexate-Lung Study Group. Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. A multicenter, case-control study. Ann Intern Med: 1997; 127 5 356 364
114. Roubille C., Haraoui B. Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature review. Semin Arthritis Rheum: 2014; 43 5 613 626
115. Caress J. B., Hobson-Webb L., Passmore L. V., Finkbiner A. P., Cartwright M. S. Case-control study of thromboembolic events associated with IV immunoglobulin. J Neurol: 2009; 256 3 339 342
116. Orbach H., Katz U., Sherer Y., Shoenfeld Y. Intravenous immunoglobulin: adverse effects and safe administration. Clin Rev Allergy Immunol: 2005; 29 3 173 184
117. Carbone J. Adverse reactions and pathogen safety of intravenous immunoglobulin. Curr Drug Saf: 2007; 2 1 9 18